热门资讯> 正文
ADARx Pharmaceuticals在大型IPO后飙升
2026-09-26 04:11
- ADARx Pharmaceuticals (ADRX) closed up ~14% on its first day of trading Friday following an upsized $446.3M IPO.
- Shares were priced at $17 but opened at $22.10. They closed at $19.35.
- The upsized IPO was for 26,250,000 shares, plus up to an additional 3,937,500 shares for the underwriters.
- ADARx's lead asset, in phase 3, is onvuzosiran, a small interfering RNA (siRNA) for hereditary angioedema. In phase 2, the company has agazisiran, another siRNA for complement-mediated diseases, including IgA nephropathy, complement 3 glomerulopathy, geographic atrophy, and paroxysmal nocturnal hemoglobinuria.
More on ADARx Pharmaceuticals
- ADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie
- Financial information for ADARx Pharmaceuticals, Inc.
推荐文章
一周财经日历 | 影响加息大事！9月大小非农数据重磅登场；美光、希音齐放榜！景旺电子、欢创科技等5只新股下周上市
美股前瞻 | 伊朗总统愿推进与美谈判！三大期指齐升；9月劲升36%！Meta创2013年来最佳月度表现；比特币一度重返8.5万美元
一图看懂 | 华夏富时港股高息ETF开启申购！入场门槛为1000港元
美股前瞻 | 联储局再传“鹰声”！美债收益率应声走高，纳指期货跌近1%；中美第八轮经贸磋商达成多项共识；Meta全面押注个人Agent
Q4净利或狂飙逾1000%！美光能否交出”炸裂“财报？三大焦点将影响股价走向
休市提醒：中秋假期来临，港股9月25日（周五）正常开市
华盛早报 | 强劲PMI催高加息预期！纳指回调1%；美财政部拟再回购60亿美元长债；SpaceX总裁套现逾5200万美元
美股前瞻 | 特朗普最新调仓曝光！抛售微软，买入英伟达；Meta科技盛会重磅来袭；高盛、德银齐看多：标普500将冲刺8000点
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
